Portal Vein Pressure
Conditions
Keywords
Terlipressinum, Portal Vein Pressure, Liver Tumor Resection
Brief summary
In this study, investigators aim to screen out the patients with portal hypertension by monitoring intraoperative PVP, and to decide the effect of Terlipressinum on the portal pressure after liver resection.
Detailed description
Liver resection is a common treatment for liver tumors. But the incidence of postoperative liver failure after hepatectomy is as high as 9-18.6%, which results in relatively high mortality rate . Portal hypertension is considered as a contraindication for hepatectomy according to the guidelines of the European Society of Hepatology and the American Society of Hepatology. Recent studies found that patients with portal hypertension were more likely to have persistent liver failure and shorter long-term survival after liver resection operation, compared to patients without portal hypertension. Most of liver cancer patients in China have disease backgroud including chronic hepatitis and cirrhosis. Among liver cancer patients, of which function is Child A or B and have indication for liver resection, 25% of them have portal hypertension.
Interventions
DRUGTerlipressinum
If the PVP is over 12 mmHg after hepatectomy, 1mg of Terlipressinum was given to patients intravenously. If the portal vein pressure is decreased by 1 mmHg, then 2mg of Terlipressinum was continuously given every day in the next 4 days after liver resection.
Sponsors
Shanghai Zhongshan Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Patients who receives liver resection. 2. PVP is more than 12mmHg in 5 minutes after liver resection.
Exclusion criteria
1. Age: \<18, \>75; 2. Portal vein tumor thrombus is confirmed by preoperative assays; 3. Obstruction of biliary tract; 4. Active hepatitis; 5. Previous history of myocardial infarction; 6. Previous history of chronic kidney disease; 7. Severe arrhythmia; 8. Any other contraindications of the Terlipressinum.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change of Portal vein pressure | 8 months | The change of the portal vein pressure before and after the use of Terlipressinum. |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of acute renal dysfunction after hepatectomy | 8 months |
| Adverse effect of Terlipressurinum | 8 months |
| Incidence of hepatic dysfunction after hepatectomy | 8 months |
Countries
China
Contacts
Primary ContactHui-Chuan Sun, MD&PhD
Outcome results
None listed